Sarcopenia Consensus Summit was a four-day consensus definition conference co-organized by the FNIH, NIA and FDA, and sponsored by 5 pharmaceutical companies (Abbott, Amgen, Eli Lilly, Merck, and Novartis). This conference was held on May 8-11, 2012 at the InterContinental Hotel - Harbor Court, Baltimore, MD. The resulting consensus definition of sarcopenia, enabled through the Biomarkers Consortium acting as a neutral convener for academia, industry, FDA, NIH, and professional societies, with useful recommendations for researchers, clinicians, and regulators.

The short term goals for the meeting are to make substantive progress toward consensus on evidence-based criteria for the diagnosis of sarcopenia and to model a collaborative process for evidence-based diagnoses of other important geriatric health problems. The long term goal was to define a pathway toward evidence-based clinical diagnostic guidelines for other complex problems of aging.

For more information about the Sarcopenia Consensus Summit, please click here >>